Welcome to the e-CCO Library!

DOP23: Decrements in quality of life associated with symptoms of Inflammatory Bowel Disease: results from the UK IBD-BOOST survey
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Roukas, C.(1)*;Miller , L.(2);Hamborg, T.(2);Gordeev, V.(1);Lindsay, J.(3);Norton, C.(4);Mihaylova, B.(1);
Created: Friday, 14 July 2023, 10:43 AM
DOP23: Long-term health consequences of COVID-19 in patients with Inflammatory Bowel Diseases – A Danish prospective population-based cohort study
Year: 2022
Source: ECCO'22
Authors: Attauabi, M.(1,2,3);Dahlerup, J.F.(4);Poulsen, A.(5);Hansen, M.R.(6);Vester-Andersen, M.K.(7);Eraslan, S.(2);Prahm, A.P.(5);Pedersen, N.(8);Larsen, L.(9);Jess, T.(9,10);Neumann, A.(11);Haderslev, K.V.(12);Molazahi, A.(13);Lødrup, A.B.(14);Glerup, H.(15);Oppfeldt, A.M.(16);Jensen, M.D.(17);Theede, K.(1,3);Kiszka-Kanowitz, M.(1,3);Seidelin, J.B.(2);Burisch, J.(1,3); Danish COVID-IBD Study Group
Created: Friday, 11 February 2022, 3:52 PM
DOP23: Myenteric plexitis and post-operative recurrence in Crohn’s disease: the role of enteric glial cells and ICAM-1
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

C. Le Berre*1, J. Pabois1, T. Durand1, E. Durieu1, M. Rolli-Derkinderen1, C. Bossard2, J. Podevin3, M. Neunlist1, I. Neveu1, P. Naveilhan1, A. Bourreille1,4

Created: Friday, 22 February 2019, 9:41 AM
DOP23: Single-cell RNA sequencing identifies an important role for class I histone-deacetylase enzymes in intestinal myofibroblasts from patients with Crohn’s Disease strictures
Year: 2021
Source: ECCO'21 Virtual
Authors: Lewis, A.(1);Pan-Castillo, B.(2);Berti, G.(2);Felice, C.(1);Gordon, H.(3);Gadhok, R.(3);Minicozzi, A.(4);Chinaleong , J.(5);Feakins, R.(6);Lindsay, J.(3);Silver, A.(1)
Created: Wednesday, 2 June 2021, 4:12 PM
DOP24 Patient-reported health-related quality-of-life outcomes with vedolizumab vs. adalimumab treatment of ulcerative colitis: Results of the VARSITY trial
Year: 2020
Source:

ECCO'20 Vienna

Authors:

E.V. Loftus Jr1, S.W. Schreiber2, S. Danese3, L. Peyrin-Biroulet4, J.F. Colombel5, B.E. Sands5, S. Wang6, J. Chen7, R.A. Lirio8

Created: Thursday, 30 January 2020, 10:12 AM
DOP24: Crohn’s Disease fistula show skewed lymphoid/myeloid balance, altered myeloid cell profiles and high TNF-α expression
Year: 2021
Source: ECCO'21 Virtual
Authors: Beckerdrs., M.(1);de Krijger, M.(1);Bemelman, W.(2);de Jonge, W.(1);Buskens, C.(2);Wildenberg, M.(1)
Created: Wednesday, 2 June 2021, 4:12 PM
DOP24: Early life exposures and risk for inflammatory bowel disease: a nested case-control study in Quebec, Canada
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Fantodji, C.(1)*;Rousseau, M.C.(1);Nicolau, B.(2);Madathil, S.(2);Benedetti, A.(3);Jantchou, P.(4);
Created: Friday, 14 July 2023, 10:43 AM
DOP24: Intestinal acidification sensed by pH-sensing receptor GPR4 contributes to fibrogenesis
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

B. Weder*1, W. T. Van Haaften2, K. Baebler1, G. Rogler3, G. Dijkstra4, P. H. Imenez Silva5, Y. Wang5, C. De Vallière3, C. Wagner5, I. Frey-Wagner3, K. Seuwen6, P. Ruiz3, M. Hausmann3

Created: Friday, 22 February 2019, 9:41 AM
DOP24: Japan prospective multicenter study for optimization of COVID-19 vaccinations based on the immune response and safety profile in Inflammatory Bowel Disease patients: Interim analyses of the J-COMBAT trial
Year: 2022
Source: ECCO'22
Authors: WatanabeDirector of division- Assistan, K.(1);Hisamatsu, T.(2);Nakase, H.(3);Nagase, K.(1);Matsuura, M.(2);Aoyama, N.(4);Kobayashi, T.(5);Sakuraba, H.(6);Yokoyama, K.(7);Nishishita, M.(8);Esaki , M.(9);Hirai, F.(10);Nagahori, M.(11);Nanjo, S.(12);Omori, T.(13);Tanida, S.(14);Yokoyama, Y.(3);Moriya, K.(15);Maemoto, A.(16);Handa, O.(17);Ohmiya, N.(18);Shinzaki, S.(19);Kato, S.(20);Tanaka, H.(21);Uraoka, T.(22);Takatsu, N.(23);Suzuki, H.(24);Takahashi, K.(25);Umeno, J.(26);Mishima, Y.(27);Tsuchida, K.(28);Fujiya, M.(29);Hiraoka, S.(30);Yamamoto, S.(31);Saruta, M.(32);Nojima, M.(33);Andoh, A.(25);
Created: Friday, 11 February 2022, 3:52 PM
DOP25 Medication use and comorbidities among elderly when compared with younger patients with inflammatory bowel disease in the TARGET-IBD cohort
Year: 2020
Source:

ECCO'20 Vienna

Authors:

E. Barnes1, J. Hanson2, M. Regueiro3, S. Saha4, B.E. Sands5, D. Rubin6, M. Dubinsky7, C. Siegel8, D. Gazis9, J. Crawford10, M. Long1

Created: Thursday, 30 January 2020, 10:12 AM
DOP25: Association of Enterobacteriaceae with Crohn’s Disease subtypes during remission
Year: 2021
Source: ECCO'21 Virtual
Authors: Pisani, A.(1);Rausch, P.(2);Ellul, S.(3);Bang, C.(2);Tabone, T.(1);Marantidis Cordina, C.(4);Zahra, G.(5);Ellul, P.(1);Franke, A.(2)
Created: Wednesday, 2 June 2021, 4:12 PM
DOP25: Clinical outcomes of COVID-19 and Impact on Disease Course in Patients with Inflammatory Bowel Disease
Year: 2022
Source: ECCO'22
Authors: Wetwittayakhlang, P.(1);Albader, F.(2);Golovics, P.(1);Drügg Hahn, G.(1);Bessissow, T.(1); Bitton, A.(1); Afif, W.(1);Wild, G.(1);LakatosPhD, P.L.(1); Inflammatory bowel disease McGill University Health Centre
Created: Friday, 11 February 2022, 3:52 PM
DOP25: Contraceptive method use according to Inflammatory Bowel Disease status among young women in the United States
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Brenner, E.(1)*;Zhang, X.(2);Long, M.(3);Dubinsky, M.(4);Kappelman, M.(2);
Created: Friday, 14 July 2023, 10:43 AM
DOP25: Unravelling vedolizumab mechanism of action in ulcerative colitis
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

M. Veny*1, A. Garrido1, H. Bassolas-Molina1, M. C. Masamunt1, M. Esteller1, M. Arroyes1, A. M. Corraliza1, E. Tristán2, A. Fernández-Clotet1, I. Ordás1, E. Ricart1, M. Esteve2, J. Panés1, A. Salas1

Created: Friday, 22 February 2019, 9:41 AM
DOP26 Real-life dosing patterns and concomitant drug use among ustekinumab-treated patients with Crohn’s disease
Year: 2020
Source:

ECCO'20 Vienna

Authors:

C.G. af Björkesten1, T. Ilus2, T. Hallinen3, E. Soini3, A. Eberl1, K. Hakala4, M. Heikura5, E. Hirsi6, A. Jussila2, M. Kellokumpu7, R. Koskela8, I. Koskinen9, V. Moilanen10, C. Nielsen11, U. Nieminen1, H. Nuutinen12, M. Heikkinen13, U.M. Suhonen14, J. Tillonen15, K. Utriainen16, I. Vihriälä17, C. Wennerström18,19, A. Borsi20, R. Nissinen21, M. Koivunen21, T. Sipponen1

Created: Thursday, 30 January 2020, 10:12 AM
DOP26: Biological therapy increases NCR+ ILC3 levels in IBD patients
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

B. Creyns*1,2, B. Verstockt2,3, J. Cremer1,2, V. Ballet3, M. Ferrante2,3, S. Vermeire2,3, J. Ceuppens1, G. Van Assche2,3, C. Breynaert1

Created: Friday, 22 February 2019, 9:41 AM
DOP26: Burden of perianal disease and perianal surgery in Crohn's disease over different therapeutic eras – a population-based study from western Hungary between 1977–2020, data from the Veszprem county cohort
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Gonczi, L.(1);Lakatos, L.(2);Golovics, P.A.(3);Pandur, T.(4);David, G.(2);Erdelyi, Z.(2);Szita, I.(2);LakatosPhD, P.L.(5)*;
Created: Friday, 14 July 2023, 10:43 AM
DOP26: COVID-19 vaccine effectiveness in Inflammatory Bowel Disease patients on tumor-necrosis factor inhibitors: Real world data from a mass-vaccination campaign
Year: 2022
Source: ECCO'22
Authors: Lev Zion, R.(1);Focht, G.(1);Lujan, R.(1);Mendelovici, A.(1);Friss, C.(1);Greenfeld, S.(2);Kariv, R.(3);Ben-Tov, A.(4,5);Matz, E.(6);Nevo, D.(7);Barak-Corren, Y.(8);Dotan, I.(9);Turner, D.(10);
Created: Friday, 11 February 2022, 3:52 PM
DOP26: The relationship between vedolizumab therapeutic drug monitoring, biomarkers of inflammation, and clinical outcomes in Inflammatory Bowel Disease in the real-world setting
Year: 2021
Source: ECCO'21 Virtual
Authors: Afif, W.(1);Marshall, J.K.(2);Kaidanovich-Beilin, O.(3);Ward, R.(3);Seow, C.(4)
Created: Wednesday, 2 June 2021, 4:12 PM
DOP27 Transanal minimally invasive surgery (TAMIS): A novel approach for treatment of pouch failure
Year: 2020
Source:

ECCO'20 Vienna

Authors:

E. Van Praag BSc1, R. Hompes1, C. Buskens1, P. Tanis1, M. Duijvestein2, W. Bemelman1

Created: Thursday, 30 January 2020, 10:12 AM